CSIMarket Company Name, Ticker, Competitors, else..
Neuropace Inc   (NASDAQ: NPCE)
Other Ticker:  
 


 

Neuropace Inc

NPCE's Financial Statements and Analysis



Neuropace Inc narrowed third quarter of 2025 net loss per share of $-0.11 compare to net loss per share of $-0.19 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.26 realized in previous quarter.


third quarter of 2025
Earnings Per Share Revenues
$ -0.11 $  27 Mill
$+0.08     $+7M     +33.05 %



Neuropace Inc 's Revenue rose by 33.05 % in third quarter of 2025 (Sep 30 2025) year on year, to $27 million and advanced by 17.45 % sequentially.


Neuropace Inc is

More on NPCE's Income Statement



Neuropace Inc in the third quarter of 2025 recorded net loss of $-3.496 million, an improvement compare to net loss of $-5.452 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-8.651 million realized in previous quarter.

More on NPCE's Growth

Neuropace Inc Inventories
Inventories grew by 50.07 % to $18 million from III. Quarter a year ago, sequentially inventories rose by 10.94 %. In Sep 30 2025 company's net cash and cash equivalents decreased by $-2 million, capital expenditures grew by -0.1-70.00%, to $0 millions compare to same quarter a year ago

More on NPCE's Cash flow Statement


Neuropace Inc does not pay out common stock dividend.

In trailing twelve-month period Neuropace Inc payed $ -0.49 cash per share, on a free-cash flow basis .

Book value fell by -5.51 % sequentially to $0.56 per share, -4.42% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.56 per share from $ 0.59.

Company issued 0.27 million shares or 0.83 % in Sep 30 2025.


• More on NPCE's Dividends

 Market Capitalization (Millions) 429
 Shares Outstanding (Millions) 33
 Total Debt (Millions $) 59
 Revenue (TTM) (Millions $) 95
 Net Income (TTM) (Millions $) -24
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 162




Neuropace Inc does not pay out common stock dividend.

In trailing twelve-month period Neuropace Inc had negative $ -0.49 cash flow per share, on a free-cash flow basis .

Book value fell by -5.51 % sequentially to $0.56 per share, -4.42% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.56 per share from $ 0.59.

Company issued 0.27 million shares or 0.83 % in Sep 30 2025.


• More on NPCE's Balance Sheets

 Market Capitalization (Millions) 429
 Shares Outstanding (Millions) 33
 Total Debt (Millions $) 59
 Revenue (TTM) (Millions $) 95
 Net Income (TTM) (Millions $) -24
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 162
   


  News about Neuropace Inc Earnings

NPCE's Remarkable Performance Steals the Show in Latest Fiscal Period!

NeuroPace Inc, a medical device company focused on epilepsy treatment, has reported its fina...

Neuropace Inc Achieves Impressive Revenue Growth and Drastically Reduces Losses in Q2 2023



Neuropace Inc, a leading player in the industry, has recently released its financial results for the second quarter of 2023. The impressive revenue growth and improved earnings per share (EPS) in this quarter signify positive developments for the company. Additionally, the reduction of losses compared to the previous year showcases Neuropace Inc's commitment to improving its financial performance. Examining the implications of these results could shed light on the company's future prospects and potential challenges.
1. Revenue Growth and EPS Improvement:
Neuropace Inc experienced a remarkable 56.588% increase in revenue, reaching $15.97 million in the second quarter of the 2023 earnings sea...

NPCE Reduces Losses in Q1 2023, Boosts Revenue by 27%2. Neuropace Inc Surpasses Expectations in Q1 2023 with Lower Losses and Increased Revenue3. Strong Performance in Q1 2023: Neuropace Inc Bounces Back with Improved Financials4. Neuropace Inc Shows Promising Results in Q1 2023, Decreases Losses and Boosts Revenue5. Q1 2023 Earnings Report: Neuropace Inc Achieves Significant Growth, Narrows Losses

Investors of Neuropace Inc can breathe a sigh of relief as the company has performed reasonably well in the first quarter of 2023 earnings season. According to the financial report for the quarter ending March 31, 2023, the company recorded a decrease in its loss per share from $-0.47 a year ago to $-0.41 per share. Further, the EPS of the company improved from $-0.44 per share in the preceding financial reporting period.
More interestingly, the revenue of Neuropace Inc increased substantially by 27.238 % to $14.47 million from $11.37 million in the comparable financial reporting period a year ago. Further, the revenue sequentially advanced by 13.16 % from $12.79 million. This massive improvement in the ...


Date modified: 2025-11-11T18:23:04+00:00




Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.